1020 related articles for article (PubMed ID: 17555947)
1. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
[TBL] [Abstract][Full Text] [Related]
2. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
Taylor D; Hanssens L; Loze JY; Pans M; L'Italien G; Marcus RN
Eur Psychiatry; 2008 Aug; 23(5):336-43. PubMed ID: 18423987
[TBL] [Abstract][Full Text] [Related]
3. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).
Wolf J; Janssen F; Lublin H; Salokangas RK; Allain H; Smeraldi E; Bernardo M; Millar H; Pans M; Adelbrecht C; Laughton J; Werner C; Maier W
Curr Med Res Opin; 2007 Oct; 23(10):2313-23. PubMed ID: 17706003
[TBL] [Abstract][Full Text] [Related]
5. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.
Peuskens J; Bervoets C; Kok F; Delatte B; Touquet G; Gillain B; de Patoul A; Halkin V; Loze JY; Vansteelandt K; Constant E
Eur Psychiatry; 2012 Oct; 27(7):506-12. PubMed ID: 21920707
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
King D; Knapp M; Thomas P; Razzouk D; Loze JY; Kan HJ; van Baardewijk M
Curr Med Res Opin; 2011 Feb; 27(2):365-74. PubMed ID: 21166610
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
10. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
[TBL] [Abstract][Full Text] [Related]
12. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Tandon R; Marcus RN; Stock EG; Riera LC; Kostic D; Pans M; McQuade RD; Nyilas M; Iwamoto T; Crandall DT
Schizophr Res; 2006 May; 84(1):77-89. PubMed ID: 16483745
[TBL] [Abstract][Full Text] [Related]
13. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
16. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
18. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
